MicroRNA miR-29b regulates diabetic aortic remodeling and stiffening.
arterial stiffness
collagen
diabetes mellitus
elastin
extracellular matrix
microRNA
non-coding RNA
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
04 Jun 2021
04 Jun 2021
Historique:
received:
18
08
2020
accepted:
19
02
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
27
3
2021
Statut:
epublish
Résumé
Patients with type 2 diabetes (T2D) are threatened by excessive cardiovascular morbidity and mortality. While accelerated arterial stiffening may represent a critical mechanistic factor driving cardiovascular risk in T2D, specific therapies to contain the underlying diabetic arterial remodeling have been elusive. The present translational study investigates the role of microRNA-29b (miR-29b) as a driver and therapeutic target of diabetic aortic remodeling and stiffening. Using a murine model (db/db mice), as well as human aortic tissue samples, we find that diabetic aortic remodeling and stiffening is associated with medial fibrosis, as well as fragmentation of aortic elastic layers. miR-29b is significantly downregulated in T2D and miR-29b repression is sufficient to induce both aortic medial fibrosis and elastin breakdown through upregulation of its direct target genes
Identifiants
pubmed: 33767915
doi: 10.1016/j.omtn.2021.02.021
pii: S2162-2531(21)00056-1
pmc: PMC7957025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-199Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
I.N.S. and U.R. are cofounders of Angiolutions GmbH. Angiolutions GmbH is an academic spin-off company developing vascular devices for aneurysm diseases. The authors declare no competing interests with the contents of this work.
Références
Circ Res. 2000 Mar 17;86(5):494-501
pubmed: 10720409
Antioxid Redox Signal. 2014 Feb 20;20(6):914-28
pubmed: 23879326
Circ Res. 2016 Aug 19;119(5):e39-75
pubmed: 27418630
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1301-1306
pubmed: 31242028
J Clin Invest. 2012 Feb;122(2):497-506
pubmed: 22269326
Front Physiol. 2018 Oct 31;9:1459
pubmed: 30429794
Circ Res. 2010 Sep 17;107(6):810-7
pubmed: 20651284
Diab Vasc Dis Res. 2018 May;15(3):214-222
pubmed: 29409329
Mol Ther. 2014 Apr;22(4):842-53
pubmed: 24445937
Circ Res. 1964 May;14:400-13
pubmed: 14156860
Microvasc Res. 2004 Sep;68(2):132-42
pubmed: 15313123
Cell Mol Biol Lett. 2019 Dec 9;24:69
pubmed: 31867046
Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):e1-e11
pubmed: 28122777
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2073-82
pubmed: 17237245
Circ Res. 2015 Aug 28;117(6):513-24
pubmed: 26208651
Cardiovasc Res. 2018 Nov 1;114(13):1702-1713
pubmed: 30052821
Physiol Rev. 2009 Jul;89(3):957-89
pubmed: 19584318
Sci Transl Med. 2012 Feb 22;4(122):122ra22
pubmed: 22357537
Cardiovasc Res. 2009 Dec 1;84(3):494-504
pubmed: 19617223
Mol Vis. 2009 Nov 28;15:2488-97
pubmed: 19956414
Cardiology. 2009;114(2):107-13
pubmed: 19451714
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Circulation. 2002 Oct 15;106(16):2085-90
pubmed: 12379578
Int J Mol Sci. 2015 Oct 23;16(10):25234-63
pubmed: 26512646
J Exp Clin Cancer Res. 2015 Jun 11;34:59
pubmed: 26063204
Cardiovasc Diabetol. 2006 Feb 17;5:3
pubmed: 16503991
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27
pubmed: 20338492
World J Diabetes. 2015 Oct 10;6(13):1246-58
pubmed: 26468341
Diabetologia. 2008 Apr;51(4):527-39
pubmed: 18239908
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32
pubmed: 18723672
Circulation. 2015 May 19;131(20):1783-95
pubmed: 25904646